Memantine, a noncompetitive NMDA receptor antagonist improves hyperammonemia‐induced encephalopathy and acute hepatic encephalopathy in rats

The aim of this study was to investigate the possible role of N‐methyl‐D‐aspartate (NMDA)‐receptor overactivity in two different experimental rat models of encephalopathy: subacute encephalopathy caused by severe hyperammonemia in portacaval‐shunted rats (AI‐PCS rats) and acute hepatic encephalopathy caused by complete liver ischemia (LIS rats). The effect of the noncompetitive NMDA‐receptor antagonist memantine (intraperitoneal [i.p.] 10‐20 mg/kg bw or intravenous [i.v.] 5 mg/kg bw) was studied on the severity of encephalopathy by assessment of clinical grading and electroencephalogram (EEG) spectral analysis, on plasma ammonia concentrations, amino acid concentrations in cerebrospinal fluid (CSF), intracranial pressure (ICP), and brain water content. Both rat models developed encephalopathy within 3 to 6 hours, associated with increased CSF glutamate and aspartate concentrations and increased ICP and brain water content. Memantine administration in AI‐PCS and LIS rats resulted in a significant improvement in clinical grading and less slowing of EEG activity (P < .05), and smaller increases in CSF glutamate (P < .05) concentrations. Moreover, ICP and brain water content were significantly lower in memantine‐treated AI‐PCS rats than in untreated AI‐PCS rats (P < .05). Memantine had no significant effect on ICP and brain water content in LIS rats, and on ammonia concentrations in both models. These results indicate that NMDA‐ receptor activation might be involved in the pathogenesis of hyperammonemia‐induced encephalopathy and of acute hepatic encephalopathy caused by LIS.

[1]  R. Chamuleau,et al.  The effects of ammonia and portal-systemic shunting on brain metabolism, neurotransmission and intracranial hypertension in hyperammonaemia-induced encephalopathy. , 1997, Journal of hepatology.

[2]  C. Parsons,et al.  Comparison of the potency, kinetics and voltage-dependency of a series of uncompetitive NMDA receptor antagonists in vitro with anticonvulsive and motor impairment activity in vivo , 1995, Neuropharmacology.

[3]  J. Kornhuber,et al.  Cerebrospinal fluid and serum concentrations of the N-methyl-d-aspartate (NMDA) receptor antagonist memantine in man , 1995, Neuroscience Letters.

[4]  P. Riederer,et al.  Noncompetitive NMDA Receptor Antagonists with Fast Open-Channel Blocking Kinetics and Strong Voltage-Dependency as Potential Therapeutic Agents for Alzheimer's Dementia , 1995, Pharmacopsychiatry.

[5]  S. Goderie,et al.  Astrocytic Swelling Due to Hypotonic or High K+ Medium Causes Inhibition of Glutamate and Aspartate Uptake and Increases Their Release , 1995, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[6]  J. J. Trout,et al.  Polyamines and NMDA receptors modulate pericapillary astrocyte swelling following cerebral cryo-injury in the rat , 1995, Journal of neurocytology.

[7]  J. Olney,et al.  Excitotoxicity and the NMDA receptor - still lethal after eight years , 1995, Trends in Neurosciences.

[8]  R. Butterworth,et al.  Ammonia‐induced brain edema and intracranial hypertension in rats after portacaval anastomosis , 1994, Hepatology.

[9]  M. J. Friedlander,et al.  Role of NO production in NMDA receptor-mediated neurotransmitter release in cerebral cortex. , 1994, Science.

[10]  C. Parsons,et al.  Memantine selectively depresses NMDA receptor-mediated responses of rat spinal neurones in vivo , 1994, Neuroscience Letters.

[11]  C. Parsons,et al.  Patch clamp studies on the kinetics and selectivity of N-methyl-d-aspartate receptor antagonism by memantine (1-amino-3,5-dimethyladamantan) , 1993, Neuropharmacology.

[12]  B. Scatton.  The NMDA receptor complex , 1993, Fundamental & clinical pharmacology.

[13]  H. Kimelberg,et al.  Role of calcium in astrocyte volume regulation and in the release of ions and amino acids , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[14]  S. Warach,et al.  Open-channel block of N-methyl-D-aspartate (NMDA) responses by memantine: therapeutic advantage against NMDA receptor-mediated neurotoxicity , 1992, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[15]  R. Butterworth,et al.  Monitoring of neurotransmitter amino acids by means of an indwelling cisterna magna catheter: A comparison of two rodent models of fulminant liver failure , 1992, Hepatology.

[16]  C. Gips,et al.  A rapid method for blood ammonia determination using the new blood ammonia checker (BAC) II. , 1992, Clinica chimica acta; international journal of clinical chemistry.

[17]  N. Deutz,et al.  Amino Acid Release from Cerebral Cortex in Experimental Acute Liver Failure, Studied by In Vivo Cerebral Cortex Microdialysis , 1992, Journal of neurochemistry.

[18]  R. Roth,et al.  Regulation of excitatory amino acid release by N-methyl-d-aspartate receptors in rat striatum: in vivo microdialysis studies , 1992, Brain Research.

[19]  R. Butterworth,et al.  Ammonia and related amino acids in the pathogenesis of brain edema in acute ischemic liver failure in rats , 1992, Hepatology.

[20]  V. Teichberg.  Glial glutamate receptors: likely actors in brain signaling , 1991, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[21]  K. Ditzler.  Efficacy and tolerability of memantine in patients with dementia syndrome. A double-blind, placebo controlled trial. , 1991, Arzneimittel-Forschung.

[22]  B D Ross,et al.  Localized 1H NMR spectroscopy in patients with chronic hepatic encephalopathy. Analysis of changes in cerebral glutamine, choline and inositols , 1991, NMR in biomedicine.

[23]  A. Baba,et al.  l-Glutamate-induced swelling of cultured astrocytes is dependent on extracellular Ca2+ , 1991, Neuroscience Letters.

[24]  A. D. de Graaf,et al.  Changes in brain metabolism during hyperammonemia and acute liver failure: Results of a comparative 1H‐NMR spectroscopy and biochemical investigation , 1990, Hepatology.

[25]  J. Viña,et al.  Early establishment of cerebral dysfunction after portacaval shunting. , 1990, The American journal of physiology.

[26]  J. Bormann,et al.  Memantine displaces [3H]MK-801 at therapeutic concentrations in postmortem human frontal cortex. , 1989, European journal of pharmacology.

[27]  D. Ganger,et al.  Effect of body temperature on brain edema and encephalopathy in the rat after hepatic devascularization. , 1989, Gastroenterology.

[28]  P. Soeters,et al.  Fully automated liquid-chromatographic determination of amino acids. , 1988, Clinical chemistry.

[29]  D. Choi.  Ionic dependence of glutamate neurotoxicity , 1987, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[30]  R. Butterworth,et al.  Ammonia: key factor in the pathogenesis of hepatic encephalopathy. , 1987, Neurochemical pathology.

[31]  C. Cotman,et al.  Pathologic concentrations of ammonium ions block l-glutamate uptake , 1985, Experimental Neurology.

[32]  A. Watanabe,et al.  Glutamic acid and glutamine levels in serum and cerebrospinal fluid in hepatic encephalopathy. , 1984, Biochemical medicine.

[33]  J. Heerikhuize,et al.  Successful ventricular application of the miniaturized controlled-delivery Accurel technique for sustained enhancement of cerebrospinal fluid peptide levels in the rat , 1984, Journal of Neuroscience Methods.

[34]  C. Cortesini,et al.  The Release and Neosynthesis of Glutamic Acid Are Increased in Experimental Models of Hepatic Encephalopathy , 1983, Journal of neurochemistry.

[35]  J. Funovics,et al.  [Changes in brain metabolism in hepatic coma]. , 1977, Chirurgisches Forum fur experimentelle und klinische Forschung.

[36]  O. Zelder,et al.  [Portacaval shunt in the rat. Methods and results]. , 1974, Zeitschrift fur Gastroenterologie.

[37]  F. Plum,et al.  α-Ketoglutaramate: Increased Concentrations in the Cerebrospinal Fluid of Patients in Hepatic Coma , 1974, Science.

[38]  L. Gjessing,et al.  The free amino acids in human cerebrospinal fluid , 1972, Journal of neurochemistry.

[39]  J. Cavanagh,et al.  THE GLUTAMATE AND GLUTAMINE CONTENT OF RAT BRAIN AFTER PORTOCAVAL ANASTOMOSIS , 1972, Journal of neurochemistry.

[40]  B. Combes,et al.  Cerebral edema: a major complication of massive hepatic necrosis. , 1971, Gastroenterology.

[41]  K. Sugita,et al.  An assessment of progression of brain edema with amino acid levels in cerebrospinal fluid and changes in electroencephalogram in an adult cat model of cold brain injury. , 1994, Acta neurochirurgica. Supplementum.

[42]  E. Dalm,et al.  Extracellular brain glutamate during acute liver failure and during acute hyperammonemia simulating acute liver failure: an experimental study based on in vivo brain dialysis. , 1994, Journal of hepatology.

[43]  W. Danysz,et al.  Are NMDA antagonistic properties relevant for antiparkinsonianlike activity in rats?—Case of amantadine and memantine , 1994, Journal of neural transmission. Parkinson's disease and dementia section.

[44]  A. Baba,et al.  L-glutamate-induced swelling of cultured astrocytes. , 1992, Advances in experimental medicine and biology.

[45]  R. Chamuleau,et al.  Quantitative analysis of EEG power spectra in experimental hepatic encephalopathy. , 1983, Neuropsychobiology.

[46]  W. Wesemann,et al.  Distribution of memantine in brain, liver, and blood of the rat. , 1982, Arzneimittel-Forschung.